The DOI matches its Crossref record.
Complex formation between protein C inhibitor and prostate‐specific antigen in vitro and in human semen
Abstract
Protein C inhibitor (PCI), a serine‐proteinase inhibitor first purified from human blood plasma, occurs at high concentrations (3–4 μM) in seminal fluid in both a high‐molecular‐mass and low‐molecular‐mass form. Immunochemical data have previously suggested that PCI in seminal plasma forms complexes with the most abundant serine proteinase in semen, prostate‐specific antigen (PSA). To provide a structural characterization of the PCI target, immunodetected as PSA, a procedure was developed to isolate low‐molecular‐mass and high‐molecular‐mass‐forms of PCI from seminal fluid. The high‐molecular‐mass form of PCI, recognized by monoclonal antibodies against PSA, was dissociated by alkaline treatment into the low‐molecular‐mass form of PCI and a 33‐kDa protein identified as PSA by 25 conclusive steps of N‐terminal sequence analysis. We developed a sensitive immunofluorometric assay (IFMA) to measure PCI‐PSA complexes in body fluids and investigated the rate at which purified PSA may form complexes with purified PCI. Formation of complexes detected by this IFMA and the appearance of SDS‐stable approximately 90‐kDa complexes paralleled loss of PSA activity recorded with chromogenic substrates. The rate of complex formation was slow compared to that reported for PCI and activated protein C, but was enhanced up to sixfold in the presence of heparin. Less than 10% of the initial PSA activity remained after 3 h incubation with a sevenfold molar excess of PCI and in the presence of heparin. In freshly collected ejaculates, the rate of PCI‐PSA complex formation measured by IFMA was similar to that observed between the purified proteins, and paralleled the appearance of SDS‐stable complexes by immunoblotting. During gel dissolution in freshly collected ejaculates, approximately 40% of immunodetected PCI becomes complexed to PSA. Although PCI is a slow inhibitor of PSA, complexes between PCI and PSA are detected at levels that correspond to an inactivation of up to 5% of the PSA activity in the ejaculate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biology of Prostate-Specific Antigen
Balk, S. P., Ko, Y.-J., & Bubley, G. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.083 · Cited by 718
Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer
Borgoño, C. A., Michael, I. P., & Diamandis, E. P. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.257.2.5 · Cited by 339
Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
McCormack, R. T., Wang, T. J., Rittenhouse, H. G., Wolfert, R. L., Finlay, J. A., Lilja, H., Okoloff, R. L., & Oesterling, J. E. (1995) · Urology · doi:10.1016/s0090-4295(99)80076-4 · Cited by 303
Self-citationRittenhouse, H. G., Finlay, J. A., Mikolajczyk, S. D., & Partin, A. W. (1998) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408369891234219 · Cited by 303
NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN
Diamandis, E. P., & Yu, H. (1997) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70373-6 · Cited by 172
Metadata
- Authors
- CHRISTENSSON, A., & LILJA, H.
- Venue
- European Journal of Biochemistry
- Publisher
- Wiley
- Published
- 1994-02
- Volume
- 220
- Issue
- 1
- Pages
- 45-53
- ISSN
- 0014-2956 (ISSN-L)
- 1432-1033
- OpenAlex
- W2047916400
- Cited by
- 170
- References
- 0
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complex formation between protein C inhibitor and prostate‐specific antigen in vitro and in human semen. https://app.cochat.ai/papers/10.1111/j.1432-1033.1994.tb18597.x
- The paper
- CHRISTENSSON, A., & LILJA, H. (1994). Complex formation between protein C inhibitor and prostate‐specific antigen in vitro and in human semen. European Journal of Biochemistry. https://doi.org/10.1111/j.1432-1033.1994.tb18597.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.